Literature DB >> 10599706

Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty.

M R Palmert1, M J Mansfield, W F Crowley, J F Crigler, J D Crawford, P A Boepple.   

Abstract

Concern has been raised that children with central precocious puberty (CPP) are prone to the development of obesity. Here we report longitudinal height, weight, and body mass index (BMI) data from 96 girls and 14 boys with CPP before, during, and after GnRH agonist (GnRHa) administration. Skinfold thickness (n = 46) and percent body fat by dual energy x-ray absorptiometry (n = 21) were determined in subsets for more accurate assessment of body composition and to validate the use of the BMI SD score as an index of body fatness in our subjects. Before the initiation of therapy (PRE), the girls with CPP had a mean BMI SD score for chronological age (CA) of 1.1+/-0.1 and for bone age (BA) of 0.1+/-0.1. By the end of the study, 12-24 months after the discontinuation of GnRHa, the mean BMI SD score was 0.9+/-0.1 for CA and 0.6+/-0.1 for BA. At the visit when GnRHa was discontinued, 41% and 22% of the girls had a BMI SD score for CA more than the 85th and 95th percentiles, respectively, indicating that obesity was present at a high rate among our subjects; the BMI SD score for CA at the PRE visit was its strongest predictor. Indeed, 86% of the girls with BMI SD score for CA above the 85th percentile when GnRHa was discontinued also had BMI SD score for CA above the 85th percentile at the PRE visit. The proportion of boys with elevated BMI SD score for CA was also high. Fifty-four percent and 31% of the SD scores were greater than the 85th and 95th percentiles after 36 months of GnRHa therapy; the BMI SD score for CA PRE had been above the 85th percentile in 71% of these overweight subjects. Obesity occurs at a high rate among children with CPP, but does not appear to be related to long term pituitary-gonadal suppression induced by GnRHa administration. Children with CPP should have a baseline BMI SD score calculated, and those at risk for obesity should be counseled appropriately.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10599706     DOI: 10.1210/jcem.84.12.6204

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Central precocious puberty following the diagnosis and treatment of paediatric cancer and central nervous system tumours: presentation and long-term outcomes.

Authors:  Wassim Chemaitilly; Thomas E Merchant; Zhenghong Li; Nicole Barnes; Gregory T Armstrong; Kirsten K Ness; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Melissa M Hudson; Charles A Sklar; Amar Gajjar
Journal:  Clin Endocrinol (Oxf)       Date:  2015-11-16       Impact factor: 3.478

2.  Growth in precocious puberty.

Authors:  Justin J Brown; Garry L Warne
Journal:  Indian J Pediatr       Date:  2006-01       Impact factor: 1.967

Review 3.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

4.  Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.

Authors:  Hae Sang Lee; Jong Seo Yoon; Jung Ki Roh; Jin Soon Hwang
Journal:  Endocrine       Date:  2016-07-22       Impact factor: 3.633

5.  Overexpression of p53 accelerates puberty in high-fat diet-fed mice through Lin28/let-7 system.

Authors:  Ting Chen; Cailong Chen; Haiying Wu; Xiuli Chen; Rongrong Xie; Fengyun Wang; Hui Sun; Linqi Chen
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-30

6.  Comparison of two different GnRH analogs' impact on final height in girls with early puberty: Triptorelin acetate vs. leuprolide acetate.

Authors:  S Aka; S Abali; A Taskin; F B Bengur; S Semiz
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Oct-Dec       Impact factor: 0.877

Review 7.  The mystery of puberty initiation: genetics and epigenetics of idiopathic central precocious puberty (ICPP).

Authors:  Sofia Leka-Emiri; George P Chrousos; Christina Kanaka-Gantenbein
Journal:  J Endocrinol Invest       Date:  2017-03-01       Impact factor: 5.467

8.  LH Dynamics in Overweight Girls with Premature Adrenarche and Slowly Progressive Sexual Precocity.

Authors:  Brian Bordini; Elizabeth Littlejohn; Robert L Rosenfield
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-19

Review 9.  Pros and cons of GnRHa treatment for early puberty in girls.

Authors:  Ruben H Willemsen; Daniela Elleri; Rachel M Williams; Ken K Ong; David B Dunger
Journal:  Nat Rev Endocrinol       Date:  2014-04-08       Impact factor: 43.330

10.  Effects of gonadotropin-releasing hormone agonist therapy on body mass index and height in girls with central precocious puberty.

Authors:  Seung Jae Lee; Eun Mi Yang; Ji Yeon Seo; Chan Jong Kim
Journal:  Chonnam Med J       Date:  2012-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.